Table Of Content

Psychiatry Research: Neuroimaging, 55:249-250 Elsevier Reviewers for 1994 We wish to acknowledge the important for publication during 1994. All outside assistance we have received from many reviewers are listed in the December issue of scientists who, along with the Editorial Psychiatry Research (Volume 54, Number 3, Board, have evaluated manuscripts submitted 1994). Author Index for 1994 Barocka, A., 55:101 Hamakawa, H., 55:41 Becker, G., 55:75 Hardin, M.T., 55:85 Becker, T., 55:75 Harris, M.J., 55:121 Berman, K.F., 55:51 Hirakawa, K., 55:1 Bernardo, M., 55:131 Hoffer, P.B., 55:181 Bidaut, L., 55:237 Hokazono, Y., 55:1 Biver, F., 55:237 Holzmann, T., 55:111 Bogdahn, U., 55:75 Hor, G., 55:111 Boyko, O.B., 55:167 Inubushi, T., 55:41, 55:223 Byrum, C.E., 55:167 Jeste, D.V., 55:121 Catafau, A.M., 55:131 John, E.R., 55:13 Charles, H.C., 55:167 Kaschka, W., 55:101 Chauchat, J.-H., 55:65 Kato, T., 55:41, 55:223 Chittilla, V., 55:167 Kosten, T.R., 55:181 Cohen, D.J., 55:85, 55:205 Krishnan, K.R.R., 55:167 Cook, LA., 55:141 Krystal, J.H., 55:181 Costa, D.C., 55:193 Lachenbruch, P.A., 55:141 Cummings, J.L., 55:141 Lamoureaux, G., 55:121 d’Amato, T., 55:65 Leckman, J.F., 55:85, 55:205 Daléry, J., 55:65 Lehr, P.P., 55:121 De la Fuente, J.M., 55:237 Leuchter, A.F., 55:141 Dierks, T., 55:153 Lomejfia, F., 55:131 Duncan, J.S., 55:85 Lotstra, F., 55:237 Dunkin, J.J., 55:141 Lufkin, R.B., 55:141 Dupont, R.M., 55:121 Luxen, A., 55:237 Early, B., 55:167 MacFall, J.R., 55:167 Easton, P., 55:13 Marie-Cardine, M., 55:65 Ebert, D., 55:101 Martin, J.-P., 55:65 Ell, P.J., 55:193 Matsumoto, K., 55:1 Feistel, H., 55:101 Maul, F.-D., 55:111 Franzek, E., 55:153 Maurer, K., 55:153 Fujimoto, T., 55:1 McMahon, T.J., 55:181 Fukuzako, H., 55:1 Mena, I., 55:141 Fukuzako, T., 55:1 Mendlewicz, J., 55:237 George, M.S., 55:193 Migneco, O., 55:141 Goldberg, T.E., 55:51 Murashita, J., 55:41, 55:223 Goldman, S., 55:237 Newton, T.F., 55:141 Gonzalez-Monclis, E., 55:131 O’Connor, P.G., 55:181 Gore, J.C., 55:205 Parashos, I., 55:167 Halpern, S., 55:121 Parellada, E., 55:131 250 Peterson, B.S., 55:85, 55:205 Takeuchi, K., 55:1 Pflug, B., 55:111 Takigawa, M., 55:1 Pilowsky, L., 55:193 Thomas, H.M., 55:181 Prichep, L. S., 55:13 Torrey, E.F., 55:51 Riddle, M.A., 55:85, 55:205 Trimble, M.R., 55:193 Robertson, M.M., 55:193 Ueyama, K., 55:1 Rochet, T., 55:65 Upchurch, L., 55:167 Rosen, M.I., 55:181 van Dyck, C.H., 55:181 Schreiner, M., 55:111 Verhoeff, N.P.L.G., 55:193 Setoain, J., 55:131 Volk, S., 55:111 Shioiri, T., 55:41, 55:223 Wallace, E.A., 55:181 Stanus, E., 55:237 Walter, D.O., 55:141 Stéber, G., 55:153 Weinberger, D.R., 55:51 Strik, W.K., 55:153 Weppner, M., 55:111 Struck, M., 55:75 Wetzles, R., 55:85 Sullivan, M., 55:181 Woods, S.W., 55:181 Takahashi, S., 55:41, 55:223 Psychiatry Research: Neuroimaging, 55:251-264 Elsevier Subject Index for 1994 Affective disorder Aging, continued bipolar subtype, event related potential, 55:13 schizophrenia, frontal lobe, 55:121 bipolar subtype, phosphorus-31 magnetic schizophrenia, single photon emission computed resonance spectroscopy, 55:41 tomography, 55:121 bipolar subtype, topographic brain mapping, 55:13 schizophrenia, temporal lobe, 55:121 bipolar subtype, ventricle-brain ratio, 55:41 single photon emission computed tomography, brainstem, ultrasound, 55:75 frontal lobe, 55:121 cingulate gyrus, melancholia, 55:101 single photon emission computed tomography, cingulate gyrus, single photon emission computed schizophrenia, 55:121 tomography, 55:101 single photon emission computed tomography, cingulate gyrus, sleep deprivation, 55:101 temporal lobe, 55:121 dorsal raphe, ultrasound, 55:75 temporal lobe, schizophrenia, 55:121 event related potential, bipolar subtype, 55:13 temporal lobe, single photon emission computed event related potential, topographic brain tomography, 55:121 mapping, 55:13 Alzheimer’s disease frontal lobe, melancholia, 55:101 electroencephalography, 55:141 frontal lobe, single photon emission computed regional cerebral blood flow, 55:141 tomography, 55:101 single photon emission computed tomography, frontal lobe, sleep deprivation, 55:101 55:141 hippocampus, single photon emission computed Amygdala tomography, 55:101 laterality, magnetic resonance imaging, T2 hippocampus, sleep deprivation, 55:101 relaxation, 55:205 magnetic resonance spectroscopy, bipolar subtype, laterality, Tourette’s syndrome, 55:205 55:41 magnetic resonance imaging, laterality, 55:205 magnetic resonance spectroscopy, phosphorus-31 , 55:41 magnetic resonance imaging, T2 relaxation, 55:205 melancholia, cingulate gyrus, 55:101 magnetic resonance imaging, Tourette’s syndrome, melancholia, frontal lobe, 55:101 55:205 melancholia, single photon emission computed Tourette’s syndrome, laterality, 55:205 tomography, 55:101 Tourette’s syndrome, magnetic resonance imaging, melancholia, sleep deprivation, 55:101 55:205 phosphorus-31 magnetic resonance spectroscopy, Tourette’s syndrome, T2 relaxation, 55:205 bipolar subtype, 55:41 Basal ganglia single photon emission computed tomography, dopamine receptors, iodobenzamide, 55:111, cingulate gyrus, 55:101 55:193 single photon emission computed tomography, dopamine receptors, motor tics, 55:193 frontal lobe, 55:101 dopamine receptors, neuroleptic response, 55:111 single photon emission computed tomography, dopamine receptors, schizophrenia, 55:1 11 hippocampus, 55:101 dopamine receptors, single photon emission single photon emission computed tomography, computed tomography, 55:111, 55:193 melancholia, 55:101 dopamine receptors, Tourette’s syndrome, 55:193 single photon emission computed tomography, iodobenzamide, dopamine receptors, 55:111, sleep deprivation, 55:101 55:193 sleep deprivation, cingulate gyrus, 55:101 iodobenzamide, motor tics, 55:193 sleep deprivation, frontal lobe, 55:101 iodobenzamide, neuroleptic response, 55:111 sleep deprivation, hippocampus, 55:101 iodobenzamide, schizophrenia, 55:111 sleep deprivation, melancholia, 55:101 iodobenzamide, single photon emission computed sleep deprivation, single photon emission tomography, 55:111, 55:193 computed tomography, 55:101 iodobenzamide, Tourette’s syndrome, 55:193 topographic brain mapping, bipolar subtype, 55:13 laterality, magnetic resonance imaging, 55:85 topographic brain mapping, event related laterality, motor tics, 55:85 potential, 55:13 laterality, Tourette’s syndrome, 55:85 ultrasound, brainstem, 55:75 magnetic resonance imaging, laterality, 55:85 ultrasound, dorsal raphe, 55:75 magnetic resonance imaging, motor tics, 55:85 ventricle-brain ratio, bipolar subtype, 55:41 magnetic resonance imaging, stereology, 55:167 ventricle-brain ratio, magnetic resonance magnetic resonance imaging, Tourette’s syndrome, imaging, 55:41 55:85 Aging magnetic resonance imaging, volume measurement frontal lobe, schizophrenia, 55:121 accuracy, 55:167 frontal lobe, single photon emission computed motor tics, laterality, 55:85 tomography, 55:121 motor tics, Tourette’s syndrome, 55:85, 55:193 252 Basal ganglia continued Buprenorphine continued neuroleptic response, dopamine receptors, 55:1 11 substance dependence, cingulate gyrus, 55:181 neuroleptic response, schizophrenia, 55:111 substance dependence, naltrexone, 55:181 neuroleptic response, single photon emission substance dependence, regional cerebral blood computed tomography, 55:111 flow, 55:181 schizophrenia, dopamine receptors, 55:111 substance dependence, single photon emission schizophrenia, iodobenzamide, 55:11 1 computed tomography, 55:181 schizophrenia, neuroleptic response, 55:11! Cerebral blood flow schizophrenia, single photon emission computed Alzheimer’s disease, electroencephalography, 55:14] tomography, 55:1 11 Alzheimer’s disease, single photon emission single photon emission computed tomography, computed tomography, 55:141 dopamine receptors, 55:111, 55:193 buprenorphine, cingulate gyrus, 55:55:181 single photon emission computed tomography, buprenorphine, single photon emission computed iodobenzamide, 55:111, 55:193 tomography, 55:18! single photon emission computed tomography, buprenorphine, substance dependence, 55:181 neuroleptic response, 55:1 11 cingulate gyrus, buprenorphine, 55:18! single photon emission computed tomography, cingulate gyrus, naltrexone, 55:181 schizophrenia, 55:111 cingulate gyrus, single photon emission computed single photon emission computed tomography, tomography, 55:181 Tourette's syndrome, 55:193 cingulate gyrus, substance dependence, 55:181 stereology, magnetic resonance imaging, 55:167 electroencephalography, Alzheimer’s disease, 55:141 stereology, volume measurement accuracy, 55:167 electroencephalography, multi-infarct dementia, Tourette’s syndrome, dopamine receptors, 55:193 55:141 Tourette’s syndrome, iodobenzamide, 55:193 electroencephalography, single photon emission Tourette's syndrome, laterality, 55:85 computed tomography, 55:141 Tourette’s syndrome, magnetic resonance imaging, frontal lobe, genetics, 55:51 55:85 frontal lobe, neuropsychology, 55:51 Tourette’s syndrome, single photon emission frontal lobe, schizophrenia, 55:51 computed tomography, 55:193 frontal lobe, twins, 55:51 volume measurement accuracy, magnetic resonance frontal lobe, Wisconsin Card Sort Test, 55:51 imaging, 55: 167 genetics, frontal lobe, 55:51 volume measurement accuracy, stereology, 55:167 genetics, hippocampus, 55:51 Borderline personality disorder genetics, neuropsychology, 55:51 epilepsy, temporal lobe, 55:237 genetics, schizophrenia, 55:51 positron emission tomography, temporal lobe, genetics, twins, 55:51 55:237 genetics, Wisconsin Card Sort Test, 55:51 temporal lobe, positron emission tomography, hippocampus, genetics, 55:51 55:237 hippocampus, neuropsychology, 55:51 Buprenorphine hippocampus, schizophrenia, 55:51 cingulate gyrus, naltrexone, 55:18! hippocampus, twins, 55:51 cingulate gyrus, regional cerebral blood flow, 55:181 memory, schizophrenia, 55:51 cingulate gyrus, single photon emission computed multi-infarct dementia, electroencephalography, tomography, 55:181 55:141 . cingulate gyrus, substance dependence, 55:181 multi-infarct dementia, single photon emission naltrexone, cingulate gyrus, 55:181 computed tomography, 55:141 naltrexone, regional cerebral blood flow, 55:181 naltrexone, cingulate gyrus, 55:18] naltrexone, single photon emission computed naltrexone, single photon emission computed tomography, 55:181 tomography, 55:18! naltrexone, substance dependence, 55:181 naltrexone, substance dependence, 55:18! regional cerebral blood flow, cingulate gyrus, neuropsychology, frontal lobe, 55:51 55:181 neuropsychology, genetics, 55:51 regional cerebral blood flow, naltrexone, 55:18] neuropsychology, hippocampus, 55:51 regional cerebral blood flow, substance dependence, neuropsychology, schizophrenia, 55:51 55:181 neuropsychology, twins, 55:51 single photon emission computed tomography, neuropsychology, Wisconsin Card Sort Test, 55:51 cingulate gyrus, 55:181 schizophrenia, frontal lobe, 55:51 single photon emission computed tomography, schizophrenia, genetics, 55:51 naltrexone, 55:181 schizophrenia, hippocampus, 55:51 single photon emission computed tomography, schizophrenia, memory, 55:51 substance dependence, 55:18] schizophrenia, neuropsychology, 55:51 Cerebral blood flow continued Cingulate gyrus continued schizophrenia, twins, 55:5! regional cerebral blood flow, naltrexone, 55:181 schizophrenia, Wisconsin Card Sort Test, 55:51 regional cerebral blood flow, substance single photon emission computed tomography, dependence, 55:181 Alzheimer’s disease, 55:141 single photon emission computed tomography, single photon emission computed tomography, affective disorder, 55:101 buprenorphine, 55:181 single photon emission computed tomography, single photon emission computed tomography, buprenorphine, 55:181 cingulate gyrus, 55:18i single photon emission computed tomography, single photon emission computed tomography, frontal lobe, 55:101 electroencephalography, 55:141 single photon emission computed tomography, single photon emission computed tomography, melancholia, 55:101 multi-infarct dementia, 55:14] single photon emission computed tomography, single photon emission computed tomography, naltrexone, 55:181 naltrexone, 55:181 single photon emission computed tomography, single photon emission computed tomography, sleep deprivation, 55:101 substance dependence, 55:18! single photon emission computed tomography, substance dependence, buprenorphine, 55:181 substance dependence, 55:181 substance dependence, cingulate gyrus sleep deprivation, affective disorder, 55:101 substance dependence, naltrexone, 55:181 sleep deprivation, frontal lobe, 55:101 substance dependence, single photon emission sleep deprivation, melancholia, 55:101 computed tomography, 55:181 sleep deprivation, single photon emission computed twins, frontal lobe, 55:51 tomography, 55:101 twins, genetics, 55:51 substance dependence, buprenorphine, 55:18] twins, hippocampus, 55:51 substance dependence, naltrexone, 55:181 twins, neuropsychology, 55:51 substance dependence, regional cerebral blood twins, schizophrenia, 55:51 flow, 55:181 twins, Wisconsin Card Sort Test, 55:51 substance dependence, single photon emission Wisconsin Card Sort Test, frontal lobe, 55:51 computed tomography, 55:181 Wisconsin Card Sort Test, genetics, 55:51 Circannual rhythms Wisconsin Card Sort Test, schizophrenia, 55:51 computed tomography, schizophrenia, 55:65 Wisconsin Card Sort Test, twins, 55:51 computed tomography, season of birth, 55:65 Cingulate gyrus computed tomography, ventricle-brain ratio, 55:65 affective disorder, frontal lobe, 55:101 schizophrenia, computed tomography, 55:65 affective disorder, melancholia, 55:101 schizophrenia, season of birth, 55:65 affective disorder, single photon emission schizophrenia, ventricle-brain ratio, 55:65 computed tomography, 55:101 season of birth, computed tomography, 55:65 affective disorder, sleep deprivation, 55:101 season of birth, schizophrenia, 55:65 buprenorphine, naltrexone, 55:181 season of birth, ventricle-brain ratio, 55:65 buprenorphine, regional cerebral blood flow, ventricle-brain ratio, schizophrenia, 55:65 55:181 ventricle-brain ratio, season of birth, 55:65 buprenorphine, single photon emission computed Computed tomography tomography, 55:181 circannual rhythm, schizophrenia, 55:65 buprenorphine, substance dependence, 55:18] circannual rhythm, ventricle-brain ratio, 55:65 frontal lobe, affective disorder, 55:101 schizophrenia, circannual rhythm, 55:65 frontal lobe, melancholia, 55:10! schizophrenia, season of birth, 55:65 frontal lobe, single photon emission computed schizophrenia, third ventricle, 55:65 tomography, 55:101 schizophrenia, ventricle-brain ratio, 55:65 frontal lobe, sleep deprivation, 55:101 season of birth, schizophrenia, 55:65 melancholia, frontal lobe, 55:101 season of birth, ventricle-brain ratio, 55:65 melancholia, single photon emission computed third ventricle, schizophrenia, 55:65 tomography, 55:101 ventricle-brain ratio, circannual rhythm, 55:65 melancholia, sleep deprivation, 55:101 ventricle-brain ratio, schizophrenia, 55:65 naltrexone, buprenorphine, 55:181 ventricle-brain ratio, season of birth, 55:65 naltrexone, regional cerebral blood flow, 55:181 Corpus callosum naltrexone, single photon emission computed basal ganglia, laterality, 55:85 tomography, 55:181 basal ganglia, magnetic resonance imaging, 55:85 naltrexone, substance dependence, 55:181 basal ganglia, motor tics, 55:85 regional cerebral blood flow, buprenorphine, basal ganglia, Tourette's syndrome, 55:85 55:181 laterality, basal ganglia, 55:85 254 Corpus callosum continued Dopamine continued laterality, magnetic resonance imaging, 55:85 schizophrenia, neuroleptic response, 55:111 laterality, motor tics, 55:85 schizophrenia, single photon emission computed laterality, Tourette’s syndrome, 55:85 tomography, 55:111 magnetic resonance imaging, basal ganglia, 55:85 single photon emission computed tomography, magnetic resonance imaging, laterality, 55:85 basal ganglia, 55:111, 55:193 magnetic resonance imaging, motor tics, 55:85 single photon emission computed tomography, magnetic resonance imaging, Tourette’s syndrome, frontal lobe, 55:111 55:85 single photon emission computed tomography, motor tics, basal ganglia, 55:85 iodobenzamide, 55:111, 55:193 motor tics, laterality, 55:85 single photon emission computed tomography, motor tics, magnetic resonance imaging, 55:85 motor tics, 55:193 Tourette's syndrome, basal ganglia, 55:85 single photon emission computed tomography, Tourette’s syndrome, laterality, 55:85 neuroleptic response, 55:111 Tourette’s syndrome, magnetic resonance imaging, single photon emission computed tomography, 55:85 schizophrenia, 55:111 Tourette’s syndrome, motor tics, 55:85 single photon emission computed tomography, Dementia. See also Alzheimer’s disease, Multi- Tourette’s syndrome, 55:193 infarct dementia Tourette’s syndrome, basal ganglia, 55:193 electrophysiology, brain mapping, 55:13 Tourette’s syndrome, motor tics, 55:193 event related potentials, topographic mapping, Tourette’s syndrome, single photon emission 55:13 computed tomography, 55:193 topographic mapping, event related potentials, Dorsal raphe 55:13 affective disorder, brainstem, 55:75 Depression. See Affective disorder affective disorder, ultrasound, 55:75 Dopamine brainstem, affective disorder, 55:75 basal ganglia, frontal lobe, 55:1 11 brainstem, ultrasound, 55:75 basal ganglia, iodobenzamide, 55:111, 55:193 ultrasound, affective disorder, 55:75 basal ganglia, motor tics, 55:193 ultrasound, brainstem, 55:75 basal ganglia, neuroleptic response, 55:111 Electroencephalography basal ganglia, schizophrenia, 55:111 alpha wave activity, schizophrenia, 55:1 basal ganglia, single photon emission computed alpha wave activity, third ventricle, 55:1 tomography, 55:111, 55:193 alpha wave activity, topographic mapping, 55:1 basal ganglia, Tourette’s syndrome, 55:193 Alzheimer’s disease, regional cerebral blood frontal lobe, basal ganglia, 55:111 flow, 55:141 frontal lobe, iodobenzamide, 55:11! Alzheimer’s disease, single photon emission frontal lobe, neuroleptic response, 55:111 computed tomography, 55:141 frontal lobe, schizophrenia, 55:111 magnetic resonance imaging, alpha wave activity, frontal lobe, single photon emission computed 55:1 tomography, 55:111 magnetic resonance imaging, schizophrenia, 55:1 iodobenzamide, basal ganglia, 55:111, 55:193 magnetic resonance imaging, slow wave activity, iodobenzamide, frontal lobe, 55:111 55:1 iodobenzamide, motor tics, 55:193 magnetic resonance imaging, third ventricle, 55:1 iodobenzamide, neuroleptic response, 55:11 1 magnetic resonance imaging, topographic iodobenzamide, schizophrenia, 55:111 mapping, 55:1 iodobenzamide, single photon emission computed multi-infarct dementia, Alzheimer’s disease, 55:141 tomography, 55:111, 55:193 multi-infarct dementia, regional cerebral blood iodobenzamide, Tourette’s syndrome, 55:193 flow, 55:141 motor tics, basal ganglia, 55:193 multi-infarct dementia, single photon emission motor tics, iodobenzamide, 55:193 computed tomography, 55:14] motor tics, single photon emission computed regional cerebral blood flow, Alzheimer’s disease, tomography, 55:193 55:141 motor tics, Tourette’s syndrome, 55:193 regional cerebral blood flow, multi-infarct neuroleptic response, basal ganglia, 55:111 dementia, 55:141 neuroleptic response, frontal lobe, 55:111 schizophrenia, alpha wave activity, 55:1 neuroleptic response, schizophrenia, 55:111 schizophrenia, magnetic resonance imaging, 55:1 neuroleptic response, single photon emission schizophrenia, slow wave activity, 55:1 computed tomography, 55:111 schizophrenia, third ventricle, 55:1 schizophrenia, basal ganglia, 55:1 11 schizophrenia, topographic mapping, 55:1 schizophrenia, frontal lobe, 55:111 single photon emission computed tomography, Alzheimer’s disease, 55:141 Electroencephalography continued Frontal lobe continued single photon emission computed tomography, amygdala, laterality, 55:205 multi-infarct dementia, 55:141 amygdala, magnetic resonance imaging, 55:205 single photon emission computed tomography, amygdala, T2 relaxation, 55:205 regional cerebral blood flow, 55:141 amygdala, Tourette’s syndrome, 55:205 slow wave activity, alpha wave activity, 55:1 basal ganglia, dopamine receptor, 55:111 slow wave activity, schizophrenia, 55:1 basal ganglia, iodobenzamide, 55:11 1 slow wave activity, third ventricle, 55:1 basal ganglia, neuroleptic response, 55:111 slow wave activity, topographic mapping, 55:1 basal ganglia, schizophrenia, 55:111 third ventricle, alpha wave activity, 55:1 basal ganglia, single photon emission computed third ventricle, magnetic resonance imaging, 55:1 tomography, 55:111 third ventricle, schizophrenia, 55:1 cingulate gyrus, affective disorder, 55:101 third ventricle, slow wave activity, 55:1 cingulate gyrus, melancholia, 55:101 third ventricle, topographic mapping, 55:1 cingulate gyrus, single photon emission computed topographic mapping, alpha wave activity, 55:1 tomography, 55:101 topographic mapping, magnetic resonance cingulate gyrus, sleep deprivation, 55:101 imaging, 55:1 dopamine receptor, basal ganglia, 55:111 topographic mapping, schizophrenia, 55:1 dopamine receptor, iodobenzamide, 55:111 topographic mapping, slow wave activity, 55:1 dopamine receptor, neuroleptic response, 55:11 1 topographic mapping, third ventricle, 55:1 dopamine receptor, schizophrenia, 55:111 Epilepsy dopamine receptor, single photon emission borderline personality disorder, positron emission computed tomography, 55:111 tomography, 55:237 genetics, hippocampus, 55:51 positron emission tomography, borderline genetics, neuropsychology, 55:51 personality disorder, 55:237 genetics, regional cerebral blood flow, 55:51 temporal lobe, positron emission tomography, genetics, schizophrenia, 55:51 $5:237 genetics, twins, 55:51 Event related potentials genetics, Wisconsin Card Sort Test, 55:51 affective disorder, bipolar subtype, 55:13 hippocampus, genetics, 55:51 affective disorder, topographic mapping, 55:13 hippocampus, neuropsychology, 55:51 bipolar subtype, topographic mapping, 55:13 hippocampus, regional cerebral blood flow, 55:51 laterality, P300, 55:153 hippocampus, schizophrenia, 55:51 laterality, schizophrenia, 55:153 hippocampus, twins, 55:51 laterality, topographic mapping, 55:153 hippocampus, Wisconsin Card Sort Test, 55:51 obsessive-compulsive disorder, topographic iodobenzamide, basal ganglia, 55:111 mapping, 55:13 iodobenzamide, dopamine receptor, 55:1 11 P300, laterality, 55:153 iodobenzamide, neuroleptic response, 55:11 1 P300, schizophrenia, 55:153 iodobenzamide, schizophrenia, 55:111 P300, topographic mapping, 55:153 iodobenzamide, single photon emission computed schizophrenia, laterality, 55:153 tomography, 55:111 schizophrenia, P300, 55:153 laterality, amygdala, 55:205 schizophrenia, topographic mapping, 55:13, 55:153 laterality, magnetic resonance imaging, 55:205 topographic mapping, affective disorder, 55:13 laterality, T2 relaxation, 55:205 topographic mapping, bipolar subtype, 55:13 laterality, Tourette’s syndrome, 55:205 topographic mapping, dementia, 55:13 magnetic resonance imaging, amygdala, 55:205 topographic mapping, laterality, 55:153 magnetic resonance imaging, laterality, 55:205 topographic mapping, obsessive-compulsive magnetic resonance imaging, T2 relaxation, 55:205 disorder, 55:13 magnetic resonance imaging, Tourette’s syndrome, topographic mapping, P300, 55:153 55:205 topographic mapping, schizophrenia, 55:13, 55:153 magnetic resonance spectroscopy, negative Frontal lobe symptoms, 55:205 affective disorder, cingulate gyrus, 55:101 magnetic resonance spectroscopy, affective disorder, melancholia, 55:101 phosphomonoesters, 55:223 affective disorder, single photon emission magnetic resonance spectroscopy, phosphorus-31, computed tomography, 55:101 55:223 affective disorder, sleep deprivation, 55:101 magnetic resonance spectroscopy, schizophrenia, aging, schizophrenia, 55:121 55:223 aging, single photon emission computed melancholia, affective disorder, 55:101 tomography, 55:121 melancholia, cingulate gyrus, 55:101 aging, temporal lobe, 55:121 256 Frontal lobe continued Frontal lobe continued melancholia, single photon emission computed single photon emission computed tomography, tomography, 55:101 cingulate gyrus, 55:101 melancholia, sleep deprivation, 55:101 single photon emission computed tomography, negative symptoms, magnetic resonance dopamine receptor, 55:111 spectroscopy, 55:223 single photon emission c< d tomography, negative symptoms, phosphomonoesters, 55:223 iodobenzamide, 55:111 negative symptoms, schizophrenia, 55:223 single photon emission computed tomography, neuroleptic response, basal ganglia, 55:111 melancholia, 55:101 neuroleptic response, dopamine receptor, 55:111 single photon emission computed tomography, neuroleptic response, iodobenzamide, 55:11! neuroleptic response, 55:111 neuroleptic response, schizophrenia, 55:11 1 single photon emission computed tomography, neuroleptic response, single photon emission schizophrenia, 55:111, 55:121, 55:131 computed tomography, 55:111 single photon emission computed tomography, neuropsychology, genetics, 55:51 sleep deprivation, 55:101 neuropsychology, hippocampus, 55:51 single photon emission computed tomography, neuropsychology, regional cerebral blood flow, temporal lobe, 55:121 55:51 single photon emission computed tomography, neuropsychology, schizophrenia, 55:51 Wisconsin Card Sort Test, 55:131 neuropsychology, twins, 55:51 sleep deprivation, affective disorder, 55:101 neuropsychology, Wisconsin Card Sort Test, 55:51 sleep deprivation, cingulate gyrus, 55:101 phosphomonoesters, magnetic resonance sleep deprivation, melancholia, 55:101 spectroscopy, 55:223 sleep deprivation, single photon emission phosphomonoesters, negative symptoms, 55:223 computed tomography, 55:101 phosphomonoesters, schizophrenia, 55:223 T2 relaxation, amygdala, 55:205 phosphorus-3!, magnetic resonance spectroscopy, T2 relaxation, laterality, 55:205 55:223 T2 relaxation, magnetic resonance imaging, regional cerebral blood flow, genetics, 55:51 55:205 regional cerebral blood flow, hippocampus, 55:51 T2 relaxation, Tourette’s syndrome, 55:205 regional cerebral blood flow, neuropsychology, temporal lobe, aging, 55:121 55:51 temporal lobe, schizophrenia, 55:121 regional cerebral blood flow, schizophrenia, 55:51 temporal lobe, single photon emission computed regional cerebral blood flow, twins, 55:51 tomography, 55:12! regional cerebral blood flow, Wisconsin Card Sort Tourette’s syndrome, amygdala, 55:205 Test, 55:51 Tourette’s syndrome, laterality, 55:205 schizophrenia, aging, 55:121 Tourette’s syndrome, magnetic resonance imaging, schizophrenia, basal ganglia, 55:111 55:205 schizophrenia, dopamine receptor, 55:1 11 Tourette’s syndrome, T2 relaxation, 55:205 schizophrenia, genetics, 55:51 twins, genetics, 55:51 schizophrenia, hippocampus, 55:51 twins, hippocampus, 55:51 schizophrenia, iodobenzamide, 55:111 twins, neuropsychology, 55:51 schizophrenia, magnetic resonance spectroscopy, twins, regional cerebral blood flow, 55:51 55:223 twins, schizophrenia, 55:51 schizophrenia, negative symptoms, 55:223 twins, Wisconsin Card Sort Test, 55:51 schizophrenia, neuroleptic response, 55:11 1 Wisconsin Card Sort Test, genetics, 55:51 schizophrenia, neuropsychology, 55:51 Wisconsin Card Sort Test, hippocampus, 55:51 schizophrenia, phosphomonoesters, 55:223 Wisconsin Card Sort Test, neuropsychology, 55:51 schizophrenia, regional cerebral blood flow, 55:51 Wisconsin Card Sort Test, regional cerebral blood schizophrenia, single photon emission computed flow, 55:51 tomography, 55:111, 55:121, 55:131 Wisconsin Card Sort Test, schizophrenia, 55:51, schizophrenia, temporal lobe, 55:12! 55:131 schizophrenia, twins, 55:51 Wisconsin Card Sort Test, single photon emission schizophrenia, Wisconsin Card Sort Test, 55:51, computed tomography, 55:131 55:131 Wisconsin Card Sort Test, twins, 55:51 single photon emission computed tomography, Genetics affective disorder, 55:101 frontal lobe, neuropsychology, 55:51 single photon emission computed tomography, frontal lobe, regional cerebral blood flow, 55:51 aging, 55:121 frontal lobe, schizophrenia, 55:51 single photon emission computed tomography, frontal lobe, Wisconsin Card Sort Test, 55:51 basal ganglia, 55:111 hippocampus, neuropsychology, 55:51 Genetics continued Hippocampus continued hippocampus, regional cerebral blood flow, 55:51 twins, regional cerebral blood flow, 55:51 hippocampus, schizophrenia, 55:51 twins, schizophrenia, 55:51 hippocampus, Wisconsin Card Sort Test, 55:51 lodobenzamide neuropsychology, frontal lobe, 55:51 basal ganglia, dopamine receptor, 55:111, 55:193 neuropsychology, hippocampus, 55:51 basal ganglia, neuroleptic response, 55:111 neuropsychology, regional cerebral blood flow, basal ganglia, schizophrenia, 55:111 55:51 basal ganglia, single photon emission computed neuropsychology, schizophrenia, 55:51 tomography, 55:111, 55:193 regional cerebral blood flow, frontal lobe, 55:51 basal ganglia, Tourette’s syndrome, 55:193 regional cerebral blood flow, hippocampus, 55:51 dopamine receptor, basal ganglia, 55:111, 55:193 regional cerebral blood flow, neuropsychology, dopamine receptor, neuroleptic response, 55:11 1 55:51 dopamine receptor, schizophrenia, 55:111 regional cerebral blood flow, schizophrenia, 55:51 dopamine receptor, single photon emission regional cerebral blood flow, Wisconsin Card Sort computed tomography, 55:111, 55:193 Test, 55:51 dopamine receptor, Tourette’s syndrome, 55:193 schizophrenia, frontal lobe, 55:51 frontal lobe, neuroleptic response, 55:11 1 schizophrenia, hippocampus, 55:51 frontal lobe, schizophrenia, 55:111 schizophrenia, neuropsychology, 55:51 frontal lobe, single photon emission computed schizophrenia, regional cerebral blood flow, 55:51 tomography, 55:111 schizophrenia, Wisconsin Card Sort Test, 55:51 motor tics, basal ganglia, 55:193 twins, frontal lobe, 55:51 motor tics, dopamine receptor, 55:193 twins, hippocampus, 55:51 motor tics, single photon emission computed twins, neuropsychology, 55:51 tomography, 55:193 twins, regional cerebral blood flow, 55:51 neuroleptic response, basal ganglia, 55:1 11 twins, schizophrenia, 55:51 neuroleptic response, dopamine receptor, 55:111 twins, Wisconsin Card Sort Test, 55:51 neuroleptic response, frontal lobe, 55:111 Wisconsin Card Sort Test, frontal lobe, 55:51 neuroleptic response, schizophrenia, 55:11! Wisconsin Card Sort Test, hippocampus neuroleptic response, single photon emission Wisconsin Card Sort Test, regional cerebral blood computed tomography, 55:111 flow, 55:51 schizophrenia, basal ganglia, 55:111 Wisconsin Card Sort Test, schizophrenia, 55:51 schizophrenia, dopamine receptor, 55:111 Hippocampus schizophrenia, frontal lobe, 55:11 1 affective disorder, single photon emission schizophrenia, neuroleptic response, 55:11 1 computed tomography, 55:101 schizophrenia, single photon emission computed affective disorder, sleep deprivation, 55:10] tomography, 55:111 genetics, neuropsychology, 55:51 single photon emission computed tomography, genetics, regional cerebral blood flow, 55:51 basal ganglia, 55:111, 55:193 genetics, schizophrenia, 55:51 single photon emission computed tomography, dopamine receptor, 55:111, 55:193 neuropsychology, regional cerebral blood flow, single photon emission computed tomography, 55:51 frontal lobe, 55:111 neuropsychology, schizophrenia, 55:51 single photon emission computed tomography, neuropsychology, twins, 55:51 neuroleptic response, 55:1 11 regional cerebral blood flow, genetics single photon emission computed tomography, regional cerebral blood flow, neuropsychology, schizophrenia, 55:111 55:51 single photon emission computed tomography, regional cerebral blood flow, schizophrenia, 55:51 Tourette’s syndrome, 55:193 schizophrenia, genetics, 55:51 Tourette’s syndrome, basal ganglia, 55:193 schizophrenia, neuropsychology, 55:51 Tourette’s syndrome, dopamine receptor, 55:193 schizophrenia, regional cerebral blood flow, 55:51 Tourette’s syndrome, motor tics, 55:193 single photon emission computed tomography, Tourette’s syndrome, single photon emission affective disorder, 55:101 computed tomography, 55:193 single photon emission computed tomography, Laterality sleep deprivation, 55:101 amygdala, frontal lobe white matter, 55:205 sleep deprivation, affective disorder, 55:101 amygdala, magnetic resonance imaging, 55:205 sleep deprivation, single photon emission amygdala, T2 relaxation, 55:205 computed tomography, 55:101 amygdala, Tourette's syndrome, 55:205 twins, genetics, 55:51 basal ganglia, magnetic resonance imaging, 55:85 twins, neuropsychology, 55:51 basal ganglia, motor tics, 55:85 258 Laterality continued Magnetic resonance imaging continued basal ganglia, Tourette’s syndrome, 55:85 amygdala, Tourette’s syndrome, 55:205 corpus callosum, magnetic resonance imaging, basal ganglia, corpus callosum, 55:85 55:85 basal ganglia, laterality, 55:85 corpus callosum, motor tics, 55:85 basal ganglia, motor tics, 55:85 corpus callosum, Tourette’s syndrome, 55:85 basal ganglia, stereology, 55: 167 event related potential, P300, 55:153 basal ganglia, Tourette’s syndrome, 55:85 event related potential, schizophrenia, 55:153 basal ganglia, volume measurement accuracy, event related potential, topographic mapping, 55:167 55:153 corpus callosum, basal ganglia, 55:85 frontal lobe white matter, amygdala, 55:205 corpus callosum, laterality, 55:85 frontal lobe white matter, magnetic resonance corpus callosum, motor tics, 55:85 imaging, 55:205 corpus callosum, Tourette’s syndrome, 55:85 frontal lobe white matter, T2 relaxation, 55:205 electroencephalography, alpha wave activity, 55:1 frontal lobe white matter, Tourette’s syndrome, electroencephalography, schizophrenia, 55:1 55:205 electroencephalography, slow wave activity, 55:1 magnetic resonance imaging, amygdala, 55:205 electroencephalography, third ventricle, 55:1 magnetic resonance imaging, basal ganglia, 55:85 electroencephalography, topographic mapping, 55:1 magnetic resonance imaging, corpus callosum, frontal lobe white matter, amygdala, 55:205 55:85 frontal lobe white matter, laterality, 55:205 magnetic resonance imaging, frontal lobe white frontal lobe white matter, T2 relaxation, 55:205 matter, 55:205 frontal lobe white matter, Tourette’s syndrome, magnetic resonance imaging, motor tics, 55:85 55:205 magnetic resonance imaging, T2 relaxation, 55:205 laterality, amygdala, 55:205 magnetic resonance imaging, Tourette’s syndrome, laterality, basal ganglia, 55:85 55:85, 55:205 laterality, corpus callosum, 55:85 motor tics, basal ganglia, 55:85 laterality, frontal lobe white matter, 55:205 motor tics, corpus callosum, 55:85 laterality, motor tics, 55:85 motor tics, magnetic resonance imaging, 55:85 laterality, T2 relaxation, 55:205 motor tics, Tourette’s syndrome, 55:85 laterality, Tourette’s syndrome, 55:85, 55:205 P300, event related potential, 55:153 magnetic resonance spectroscopy, P300, schizophrenia, 55:153 phosphomonoesters, 55:41 P300, topographic mapping, 55:153 motor tics, basal ganglia, 55:85 schizophrenia, event related potential, 55:153 motor tics, laterality, 55:85 schizophrenia, P300, 55:153 motor tics, Tourette’s syndrome, 55:85 schizophrenia, topographic mapping, 55:153 phosphomonoesters, magnetic resonance T2 relaxation, amygdala, 55:205 spectroscopy, 55:41 T2 relaxation, frontal lobe white matter, 55:205 schizophrenia, alpha wave activity, 55:1 T2 relaxation, magnetic resonance imaging, 55:205 schizophrenia, electroencephalography, 55:1 T2 relaxation, Tourette's syndrome, 55:205 schizophrenia, slow wave activity, 55:1 topographic mapping, event related potential, schizophrenia, third ventricle, 55:1 55:153 schizophrenia, topographic mapping, 55:1 topographic mapping, P300, 55:153 slow wave activity, alpha wave activity, 55:1 topographic mapping, schizophrenia, 55:153 slow wave activity, electroencephalography, 55:1 Tourette’s syndrome, amygdala, 55:205 slow wave activity, schizophrenia, 55:1 Tourette’s syndrome, basal ganglia, 55:85 slow wave activity, third ventricle, 55:1 Tourette’s syndrome, corpus callosum, 55:85 slow wave activity, topographic mapping, 55:1 Tourette’s syndrome, frontal lobe white matter, stereology, basal ganglia, 55:167 55:205 stereology, volume measurement accuracy, 55:167 Tourette’s syndrome, magnetic resonance imaging, T2 relaxation, amygdala, 55:205 55:85, 55:205 T2 relaxation, frontal lobe white matter, 55:205 Tourette’s syndrome, motor tics, 55:85 T2 relaxation, laterality, 55:205 Tourette’s syndrome, T2 relaxation, 55:205 T2 relaxation, Tourette’s syndrome, 55:205 Magnetic resonance imaging third ventricle, alpha wave activity, 55:1 alpha wave activity, electroencephalography, 55:1 third ventricle, electroencephalography, 55:1 alpha wave activity, schizophrenia, 55:1 third ventricle, schizophrenia, 55:1 alpha wave activity, topographic mapping, 55:1 third ventricle, slow wave activity, 55:1 amygdala, frontal lobe white matter, 55:205 third ventricle, topographic mapping, 55:1 amygdala, laterality, 55:205 topographic mapping, alpha wave activity, 55:1 amygdala, T2 relaxation, 55:205 topographic mapping, electroencephalography, 55:1